Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02652819
Recruitment Status : Completed
First Posted : January 12, 2016
Last Update Posted : August 24, 2017
Sponsor:
Information provided by (Responsible Party):
FibroGen

Brief Summary:
This is a randomized, multicenter, double-blind, placebo-controlled study of the treatment of anemia in subjects with CKD not on dialysis, with treatment up to 52 weeks.

Condition or disease Intervention/treatment Phase
Anemia Drug: FG-4592 Drug: Placebo Phase 3

Detailed Description:

This is a randomized, multicenter, double-blind, placebo-controlled study of the treatment of anemia in subjects with CKD not on dialysis.

Eligible subjects are randomized to FG-4592 or placebo at a ratio of 2:1. The primary endpoint is change in Hb from baseline to the average level during Weeks 7 to 9 inclusive.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 154 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
Study Start Date : December 2015
Actual Primary Completion Date : January 24, 2017
Actual Study Completion Date : June 13, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: FG-4592
Intervention is investigational treatment FG-4592
Drug: FG-4592
Placebo Comparator: Placebo
Double blinded placebo control
Drug: Placebo



Primary Outcome Measures :
  1. Change in Hb from baseline to the average level [ Time Frame: Weeks 7 to 9 inclusive. ]
    Change in Hb from baseline to the average level


Secondary Outcome Measures :
  1. The proportion of subjects who achieve a confirmed Hb response [ Time Frame: up to and including Week 9 ]
    The proportion of subjects who achieve a confirmed Hb response

  2. Proportion of subjects with mean Hb ≥10.0 g/dL [ Time Frame: Weeks 7 to 9 ]
    Proportion of subjects with mean Hb ≥10.0 g/dL

  3. Mean change from baseline in low-density lipoprotein (LDL) cholesterol averaged [ Time Frame: Weeks 7 to 9 ]
    Mean change from baseline in low-density lipoprotein (LDL) cholesterol averaged

  4. Effect on iron metabolism [ Time Frame: Week 9 ]
    Measurement of serum iron

  5. Survey (SF-36) Physical Functioning (PF) subscore measured in Week 9 in the Full Analysis Set (FAS) subjects with baseline PF subscore below 35 [ Time Frame: Week 9 ]
    Survey (SF-36) Physical Functioning (PF) subscore measured in Week 9 in the Full Analysis Set (FAS) subjects with baseline PF subscore below 35

  6. Mean change from baseline in SF-36 vitality subscore measured in Week 9 in FAS subjects with baseline vitality subscore below 50. [ Time Frame: Week 9 ]
    Mean change from baseline in SF-36 vitality subscore measured in Week 9 in FAS subjects with baseline vitality subscore below 50.

  7. Mean change from baseline in mean arterial blood pressure [ Time Frame: Weeks 7 to 9 ]
    Mean change from baseline in mean arterial blood pressure

  8. Proportion of subjects who received rescue therapy (composite of blood transfusion, ESA use, and IV iron) [ Time Frame: Up to Week 9 ]
    Proportion of subjects who received rescue therapy (composite of blood transfusion, ESA use, and IV iron)

  9. Percent of subjects with treatment-emergent adverse events (TEAEs). [ Time Frame: Week 1 up to Week 53 ]
    Percent of subjects with treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)

  10. Number of subjects with treatment-emergent adverse events (TEAEs). [ Time Frame: Week 1 up to Week 53 ]
    Number of subjects with treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)

  11. Changes from baseline in vital signs [ Time Frame: Week 1 up to Week 53 ]
    Measurement of vital signs

  12. Changes from baseline in ECG findings [ Time Frame: Week 1 up to Week 53 ]
    ECG recordings

  13. Changes from baseline in clinical laboratory values [ Time Frame: Week 1 up to Week 53 ]
    Clinical laboratory values

  14. Proportion of subjects on rescue therapy [ Time Frame: Week 1 up to Week 53 ]
    Proportion of subjects on rescue therapy

  15. Time to rescue therapy from date of first dose [ Time Frame: Week 1 up to Week 53 ]
    Time to rescue therapy from date of first dose



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ages 18 to 75 years
  2. Subject has voluntarily signed and dated an informed consent form (ICF), approved by an Ethics Committee (EC), after the nature of the study has been explained and the subject has had the opportunity to ask questions.
  3. Diagnosis of chronic kidney disease, with Kidney Disease Outcomes Quality Initiative (KDOQI) Stage 3, 4, or 5, not receiving dialysis; with an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 estimated using the abbreviated 4-variable Modification of Diet in Renal Disease (MDRD) equation.
  4. No use of an erythropoiesis-stimulating agent (ESA) for at least 5 weeks before randomization.
  5. Mean of the two most recent Hb values during the Screening Period obtained at least 6 days apart must be ≥7.0 g/dL and <10 g/dL.
  6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5 x upper limit of normal (ULN), and normal total bilirubin at screening visit (based on central laboratory results).
  7. Body weight: 40 to 100 kg inclusive.
  8. Subjects agreeing not to start taking any new Traditional Chinese Medicine (TCM) for anemia and not to change dose, schedule, or brand of any prescreening TCM for anemia from beginning of Screening Period through end of Follow-up Period without approval of the FibroGen China Medical Monitor.

Exclusion Criteria:

  1. Any clinically significant infection or evidence of an active underlying infection.
  2. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab).
  3. Chronic liver disease.
  4. New York Heart Association Class III or IV congestive heart failure.
  5. Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thromboembolic event (eg, deep venous thrombosis or pulmonary embolism) within 52 weeks prior to Day 1.
  6. Uncontrolled hypertension in the opinion of the investigator (eg, that requires change in anti-hypertensive medication within 2 weeks prior to randomization).
  7. Diagnosis or suspicion (eg, complex kidney cyst of Bosniak Category II or higher) of renal cell carcinoma as shown on screening renal ultrasound.
  8. History of malignancy except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, or in situ cancer at any site.
  9. Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (eg, systemic lupus erythematosis [SLE], rheumatoid arthritis, celiac disease).
  10. Clinically significant gastrointestinal bleeding.
  11. Known history of myelodysplastic syndrome, multiple myeloma, hereditary hematologic disease such as thalassemia, sickle cell anemia, pure red cell aplasia, or other known causes for anemia other than CKD, hemosiderosis, hemochromatosis, known coagulation disorder, or hypercoagulable condition.
  12. Any prior functioning organ transplant or a scheduled organ transplantation, or anephric.
  13. Anticipated elective surgery that could lead to significant blood loss during the study period.
  14. Anticipated use of dapsone or acetaminophen (paracetamol) >2.0 g/day, or >500 mg per dose repeated every 6 hours for more than 3 days.
  15. Serum albumin <2.5 g/dL.
  16. Androgen, deferoxamine, deferiprone, or deferasirox therapy within 12 weeks prior to Day 1.
  17. Life expectancy of <12 months.
  18. Blood transfusion within 12 weeks prior to Day 1 or anticipated need for transfusion.
  19. IV iron supplement during the Screening Period and /or unwilling to withhold IV iron.
  20. Immune suppressive or systematic steroid treatment within 12 weeks prior to Day 1.
  21. History of alcohol or drug abuse within the past 2 years and inability to avoid consumption of more than >3 alcoholic beverages per day.
  22. Prior treatment with FG-4592 or any hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).
  23. Use of an investigational medication or treatment, participation in an investigational interventional study, or carryover effect of an investigational treatment expected during the study.
  24. Women who are pregnant or breastfeeding.
  25. Women of childbearing potential and men with sexual partners of child bearing potential who are not using adequate contraception.
  26. Any medical condition that, in the opinion of the investigator, may pose a safety risk to a subject in this study, may confound efficacy or safety assessment, or may interfere with study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02652819


Locations
Show Show 30 study locations
Sponsors and Collaborators
FibroGen
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: FibroGen
ClinicalTrials.gov Identifier: NCT02652819    
Other Study ID Numbers: FGCL-4592-808
First Posted: January 12, 2016    Key Record Dates
Last Update Posted: August 24, 2017
Last Verified: August 2017
Keywords provided by FibroGen:
Chronic Kidney Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Anemia
Hematologic Diseases
Urologic Diseases
Renal Insufficiency